Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Should Healthcare Pricing Be More Transparent?

Healthcare prices have continued to rise in the United States in recent years, and no solution has been agreed upon. Making a complicated situation even hard to solve is the fact that the supply chain is much more complex in healthcare than in the exchange of other goods and services. One of the major…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Healthcare prices have continued to rise in the United States in recent years, and no solution has been agreed upon. Making a complicated situation even hard to solve is the fact that the supply chain is much more complex in healthcare than in the exchange of other goods and services.

One of the major qualms about healthcare pricing is its lack of transparency. The negotiated rates between pharmaceutical companies and hospitals, insurers and pharmacies are private. This seemingly makes it difficult for consumers to shop around for lower prices.

A new executive order signed in June calls on the Department of Health and Human Services to force these negotiated rates to be publicized. This is designed to increase transparency of price and create market competition. Ideally, this will lower prices for consumers, but consensus has is hard to come by on the topic.

“Some states have already passed price transparency laws, like New Hampshire and some others, and again the story isn’t that great, at least the evaluation suggests they haven’t made an enormous impact or any impact at all on prices,” Mark Pauly, a professor of healthcare management at the Wharton School of Business at the University of Pennsylvania said.

Industry insiders are unsure of the impacts this transparency will have. Due to the nature of insurance and the way drug prices are established, transparency may not yield true competition, according to Pauly.

“You can’t look up in the Wall Street Journal, ‘what’s the going price today for a hospital day or a doctor visit’,” Pauly said. “These things are negotiated and typically the market structure for hospitals is one of oligopoly, with just a few hospitals in a typical town.”

The executive order did not spell out specifics but asked HHS to develop a policy that increases transparency.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @HealthMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512